U.S. Supreme Court opinions in Mayo Collaborative Services v. Prometheus Laboratories, Inc., Association for Molecular Pathology v. Myriad Genetics, Inc., and Alice Corporation Pty. Ltd. V. CLS Bank International et al., produced significant challenges to and unpredictability in obtaining and enforcing patent protection in areas including precision medicine, diagnostics, AI, and pharmaceutical treatments. The Patent Eligibility Restoration Act of 2025 (PERA), S. 1546 and the identical H.R. 3152, seek to address these challenges by rewriting 35 U.S.C. § 101 to eliminate all of these “judicial exceptions to patent eligibility.”
For foreign companies holding trademarks, patents, industrial designs, or other intellectual property assets in Brazil, detecting an infringement can trigger an almost automatic reaction: filing a lawsuit. Although resorting to the courts is an important tool for protecting intellectual property rights, it does not necessarily need to be the first step.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision Tuesday in Cocona, Inc. v. VF Outdoor, LLC, affirming a judgment of the U.S. District Court for the District of Colorado that held three claims of a waterproof, breathable membrane patent invalid as indefinite. Circuit Judge Stark wrote for the court, joined by Circuit Judges Lourie and Stoll, and agreed with the district court that the asserted claims recited a numerical range for moisture vapor transmission rate (MVTR) without specifying a method for measuring it.
The full Senate Judiciary Committee today heard from five witnesses who urged senators to take action to curb pharmaceutical industry and pharmacy benefit manager (PBM) practices, which they alternately blamed for high U.S. drug costs. While some senators warned that targeting drug makers could have unintended consequences, most supported moving quickly on legislation they claim would lower prices for U.S. consumers, a claim industry has called a “myth”.
Critics of the pharmaceutical patent system often claim that manufacturers use large patent portfolios to delay competition. A new paper in the Journal of Law and the Biosciences offers the latest version of that argument, focusing specifically on biologics. The authors compare biologic patent portfolios in the United States, Europe, and Japan. They find that the largest patent portfolios are in the United States—and that biologics are associated with more patents than traditional small-molecule drugs. This may be true, but it does not demonstrate that a problem exists.
Today, the U.S. Supreme Court issued an order list including denials of a pair of petitions for writ of certiorari challenging subject matter eligibility analyses under 35 U.S.C. § 101 by the U.S. Court of Appeals for the Federal Circuit. These denials continue the Court’s trend of ignoring loud alarms raised regarding the Federal Circuit’s application of the Court’s two-step patentability test under Alice Corp. v. CLS Bank International, especially the intra-circuit development of conflicting standards for analyzing subject matter eligibility of computer-related inventions.
The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision on Friday, November 13, in In re Netlist, Inc., affirming the Patent Trial and Appeal Board’s (PTAB) determination that all challenged claims of two Netlist memory module patents are unpatentable as obvious. Circuit Judge Dyk wrote for the court, joined by Circuit Judges Linn and Chen, and rejected Netlist’s argument that the PTAB erred in finding a motivation to combine since the combination would be inoperable for the intended purpose of the primary reference and would lose that reference’s key benefits.
Attribution uncertainty should be treated as a distinct source of intellectual property risk and priced into the valuation of AI-assisted inventions. When an invention emerges from a workflow in which human contributions were not documented, an inventorship error can threaten patent validity and, in some circumstances, may not be correctable. A patent is worth less if its owner cannot reliably establish who invented the claimed subject matter, which matters to buyers, licensees, lenders, insurers, and technology-transfer offices alike.
Although U.S. Patent and Trademark Office (USPTO) Director John Squires just officially announced last week that former counsel to Judge Pauline Newman, Greg Dolin, will be the new Deputy General Counsel and Solicitor, following the appointment of John Duffy as General Counsel last month, nearly 14 months after Squires became Director on September 22, 2025, the agency continues to operate with significant leadership vacancies, temporary appointments, and weakened oversight.
On Tuesday, a memorandum issued to administrative patent judges (APJs) of the Patent Trial and Appeal Board (PTAB) by U.S. Patent and Trademark Office Director John Squires and USPTO’s General Counsel John Duffy announced that effective November 16, 2026, Director Squires would be relinquishing direct oversight on merits-based PTAB institution decisions to PTAB panels. The decision to return institution decisions back to the PTAB panels themselves has been in the works for several months, as was first reported by IPWatchdog in September. Giving PTAB panels the authority to decide which cases to institute comes just more than one-year after Squires centralized the decision-making power in the Director’s Office.
Congress may soon abandon a principle that has guided the U.S. legal system for generations: the ability to obtain and enforce patent rights should not depend on the type of technology being invented. Straying from this core tenet risks weakening a key competitive advantage of the American innovation economy.
Every U.S. Patent and Trademark Office (USPTO) Director leaves office. Very few leave a legacy that could fundamentally change the future of American innovation. Director John A. Squires has an extraordinary opportunity to do just that. For more than a decade, independent inventors, startups, small businesses, universities, and those investing in American innovation have asked Congress to address the unintended consequences of the America Invents Act (AIA) and the Patent Trial and Appeal Board (PTAB). Congress held hearings. Members acknowledged the problems. Legislation was introduced. Organizations rallied behind reform. Year after year, inventors traveled to Washington, told their stories, and pleaded for meaningful change. And year after year, the problems remained. Then came Director Squires.
Technology collaboration between the United States and Korea has grown quickly, from semiconductors and artificial intelligence to biotechnology and advanced manufacturing. More joint research agreements are being signed, but the importance of their IP provisions is often overlooked. This can cause problems later, because the two countries have different legal rules that even experienced counsel can miss.
Earlier this year, with an effective date of April 9, 2026, the United States Patent and Trademark Office (USPTO) introduced the Patent Cooperation Treaty (PCT) Informed Examination Request (PIER) Pilot Program. Curiously, while most USPTO pilot programs allow the applicant to opt in or opt out, the PIER Pilot Program precludes input from the applicant on the matter and rather imposes itself on the applicant. The USPTO decides which applications will take part in the PIER Pilot Program, and the decision is not challengeable.
One day after her petition for rehearing was denied by the U.S. Court of Appeals for the Federal Circuit (CAFC), pro se inventor Carrie Hafeman has filed a petition for Extraordinary Director Review and Sua Sponte Review with the U.S. Patent and Trademark Office (USPTO). The petition asks the Director to vacate institution and the Final Written Decisions in six related inter partes reviews (IPRs) due to alleged Sotera Stipulation violations by Google and Microsoft.